Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
MD Hellmann, TE Ciuleanu, A Pluzanski… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …